Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy

In a previous study, we determined that major pathologic response (MPR) as indicated by the percentage of residual viable tumor cells predicted overall survival (OS) in patients with non‐small‐cell lung cancer (NSCLC) who received neoadjuvant chemotherapy. In this study, we assessed whether two gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Pataer, Apar, Shao, Ruping, Correa, Arlene M., Behrens, Carmen, Roth, Jack A., Vaporciyan, Ara A., Wistuba, Ignacio I., Swisher, Stephen G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010873/
https://www.ncbi.nlm.nih.gov/pubmed/29673125
http://dx.doi.org/10.1002/cam4.1505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010873/
https://www.ncbi.nlm.nih.gov/pubmed/29673125
http://dx.doi.org/10.1002/cam4.1505

Ejemplares similares